Califf Nomination Hearing Expected Before Holiday Season
This article was originally published in The Rose Sheet
Executive Summary
The Senate HELP Committee has competing priorities, but the FDA commissioner nominee still seems to have a smooth path to confirmation.
You may also be interested in...
Oral History Of Drug Development: FDA’s Califf Wants Woodcock, Temple To Share Their Stories
In an interview with “The Pink Sheet,” new deputy commissioner for medical products says FDA needs better ways of helping stakeholders, public understand agency thinking.
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.
Parallel Scientific Advice: Is The EMA User Fee Impacting Interest?
EMA charges participants to receive scientific advice through the fledgling program, unlike the US FDA, which may not fit the budgets of some complex generic sponsors. At the same time, sponsors also may simply not be aware the program exists yet.